News / Media
EXINDA THERAPEUTICS Published Papers & Media
Scientific Research Driving Innovative Treatments
Here we have gathered a selection of publications and media relevant to our company and research.
PUBLICATIONS
June 15, 2024
Comparable Efficacy of Oral Bendamustine versus Intravenous Administration in Treating Hematologic Malignancies
The purpose of this study was to analyze potential differences in antitumor efficacy and pharmacokinetics between intravenous (IV) bendamustine (BEN) and a novel orally administered bendamustine agent (PO) that is utilizing the beneficial properties of superstaturated solid dispersions formulated in nanoparticles.
November 22, 2023
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in combination with fludarabine (Flu) (CY-FLU). While cyclophosphamide (CY) possesses lymphotoxic effects, it concurrently preserves regulatory T cell activity, potentially affecting the efficacy of CAR-T cells. Moreover, the use of fludarabine (FLU)…
April 3, 2021
Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
Bendamustine (BEN) is a unique alkylating agent with efficacy against a broad range of hematological malignancies, although investigations have only recently started to delve into its immunomodulatory effects. These immunomodulatory properties of BEN in the context of hematopoietic cell transplantation (HCT) are reviewed here. Pre- and post-transplant use of BEN in multiple murine models …
NEWS
September 10, 2024
Exinda Attends Clinical Trials in Rare Diseases 2024 Event
This event in SF explores the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions.
